From Adjuvant to Metastatic in Melanoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Immune Checkpoint Inhibition

The Metastatic Setting Dosing

CheckMate-067 4-Year Survival Data by PD-L1 Expression

CheckMate-067 4-Year Survival Data

Brain Metastases CheckMate 204

Brain Metastases Australian ABC Trial

Brain Metastases Implications for Practice

Duration of Therapy

Duration of Therapy (cont)

Duration of Therapy Implications for Practice

The Adjuvant Setting KEYNOTE-054

The Adjuvant Setting CheckMate-238

Considerations in the Adjuvant Setting

Considerations in the Adjuvant Setting (cont)

Treating Patients With BRAF-Positive Disease

Emerging Approaches

Thoughts on When Trials of Investigational Drugs Should Progress to Phase 3

Emerging Approaches (cont)

irAEs

Working Together as a Team

Guidelines for Identifying and Managing irAEs

Communication

Case Example A Patient With Colitis

Concluding Remarks

Abbreviations

Abbreviations (cont)